Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.61 |
| ▸ | TUBB | P07437 | 3/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.61 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.61 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.61 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.61 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.61 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.61 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329883 | 0.89 | TUBB4A (0.57) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL29956530 | 0.87 | GPR17 (0.59) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL9253578 | 0.87 | ALOX15 (0.72) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL25207025 | 0.84 | ALOX15 (0.57) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL29955715 | 0.83 | ALOX15 (0.74) | KDM4EHSD17B10ALDH1A1ALOX15HPGD | |
| SCHEMBL22346720 | 0.83 | ALOX15 (0.53) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL25206647 | 0.81 | ALOX15 (0.51) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL1306979 | 0.80 | ALOX15 (0.50) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL29955020 | 0.80 | MEN1 (0.61) | KDM4EMAPTHSD17B10GAAALDH1A1 | |
| SCHEMBL3036356 | 0.80 | KDM4E (0.70) | KDM4EMAPTHSD17B10GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| CN-116249531-A | Compositions and methods for activating pyruvate kinase | 密执安大学评议会 | 2023-06-09 | — | — | CN | disclosed |
| EP-4185293-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | The Regents of The University of Michigan (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022020424-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-27 | — | — | WO | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20030139609-A1 | Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | PTGIR, S1PR1, TBXA2R | KDM4E 1436/4885MAPT 4739/4885HSD17B10 3950/4885 |
| US-20030139609-A1 | Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles | DUT, CYC1, DHRS9 | KDM4E 396/4885MAPT 4875/4885HSD17B10 1073/4885 |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | S1PR1, S1PR3, S1PR2 | KDM4E 3596/4885MAPT 4437/4885HSD17B10 4056/4885 |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | KDM4E 1883/4885MAPT 2067/4885HSD17B10 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.